Precision Bio rises after Phase 1/2 data for gene editing therapy in OTC deficiency

More on Precision BioSciences

• Seeking Alpha’s Quant Rating on Precision BioSciences
• Historical earnings data for Precision BioSciences
• Financial information for Precision BioSciences

Seeking Alpha | January 10, 2025

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

DURHAM, N.C., January 09, 2025--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that its partner iECURE has reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study. ECUR-506 is iECURE’s in vivo gene insertion program

Yahoo | January 9, 2025

iECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency

PHILADELPHIA, January 09, 2025--iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with significant unmet need, today reported preliminary findings from the first infant dosed in the ongoing OTC-HOPE Phase 1/2 study of ECUR-506, the company’s clinical candidate designed to treat neonatal onset ornithine transcarbamylase (OTC) deficiency. Treatment with ECUR-506 was generally well tolerated in

Yahoo | January 9, 2025

Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial

The company is currently recruiting subjects in Moldova.

Yahoo | December 19, 2024

Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B

DURHAM, N.C., December 18, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it has received Clinical Trial Application (CTA) approval in Hong Kong to study PBGENE-HBV in the ongoing ELIMINATE-B Phase I trial. PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B b

Yahoo | December 18, 2024

Precision BioSciences to Participate in Upcoming November Investor Conferences

DURHAM, N.C., November 21, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the following upcoming investor conferences.

Yahoo | November 21, 2024

Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B

DURHAM, N.C., November 15, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today will present preclinical data supporting the advancement of PBGENE-HBV into clinical development. The Company will also outline the design of its first-in-human study, ELIMINATE-B, in patients with chronic hepatitis B. Company management will present these up

Yahoo | November 15, 2024

Precision BioSciences (DTIL) Reports Q3 Loss, Misses Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -258.23% and 93.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 4, 2024

Precision BioSciences: Q3 Earnings Snapshot

DURHAM, N.C. (AP) — Precision BioSciences Inc. DTIL) on Monday reported a loss of $16.4 million in its third quarter. The Durham, North Carolina-based company said it had a loss of $2.25 per share.

Yahoo | November 4, 2024

Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

DURHAM, N.C., November 04, 2024--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

Yahoo | November 4, 2024